Persistent dystonia and basal ganglia involvement following metronidazole induced encephalopathy

[1]  F. Amin,et al.  Metronidazole-induced encephalopathy: a systematic review , 2018, Journal of Neurology.

[2]  Young Eun Kim,et al.  Metronidazole-Induced Craniocervical Myoclonus with Reversible Bilateral Dentate Nucleus Lesions , 2017, Journal of movement disorders.

[3]  S. Das,et al.  Clinical and Neuroradiological Spectrum of Metronidazole Induced Encephalopathy: Our Experience and the Review of Literature. , 2016, Journal of clinical and diagnostic research : JCDR.

[4]  Shigeaki Suzuki,et al.  Metronidazole‐induced encephalopathy and myoclonus: Case report and a review of the literature , 2015 .

[5]  N. Fischbein,et al.  Metronidazole-Induced Encephalopathy: Not Always a Reversible Situation , 2015, Neurocritical Care.

[6]  W. Tatum,et al.  Nonconvulsive Status With Metronidazole , 2013, The Neurohospitalist.

[7]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[8]  A. Kuriyama,et al.  Metronidazole-Induced Central Nervous System Toxicity: A Systematic Review , 2011, Clinical neuropharmacology.

[9]  M. Miranda,et al.  Movement disorders as a manifestation of metronidazole‐induced encephalopathy in a patient with chronic liver disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[10]  J. Ferro,et al.  Reversible iatrogenic subacute cerebellar syndrome, myoclonus and MRI findings following metronidazole administration , 2009, BMJ Case Reports.

[11]  J. Meulenbelt,et al.  Irreversible encephalopathy after treatment with high-dose intravenous metronidazole. , 2010, Clinical therapeutics.